#insulin4all USA
Patients vs. Pharma: Hagens Berman files complaint against 'Big Three' insulin producers
30 Jan 2017, 9:15 p.m. in #insulin4all USA, News & Statements by T1International
The law firm Hagens Berman has filed a complaint against Eli Lilly, Novo Nordisk, and Sanofi, the ‘big three’ pharmaceutical companies that hold a near-monopoly on the insulin market. People living with type 1 diabetes will be the plaintiffs in this class action lawsuit, which alleges that Eli Lilly, Novo Nordisk and Sanofi have unjustly inflated their prices. Read more
Eli Lilly and Novo Nordisk: More Empty Promises
19 Dec 2016, 9:01 a.m. in #insulin4all USA, News & Statements by Elizabeth Pfiester
Outrage at soaring insulin prices in the USA has been increasing. More patients and families are speaking out against unaffordable costs for life-saving medication than ever before. In response, two of the 'Big Three' insulin makers (who control over 90% of the insulin market) have recently made moves to combat this anger. Read more
Pharmadness: Your Chance to be a Pharma Company CEO
12 Dec 2016, 11:21 a.m. in #insulin4all USA, News & Statements by Elizabeth Pfiester
Last month the Missing Medicines campaign, of which T1International is proudly a member, launched a new interactive game to illustrate the problems with the global research and development model. This experience is something that everyone should a few minutes to try. Read more
T1International Statement on ADA Insulin Price Petition
18 Nov 2016, 8:24 a.m. in #insulin4all USA, News & Statements by T1International
It is fantastic to see a large diabetes organization speaking out in this way. However, we feel that the ADA’s language around the call for price transparency does not go far enough. Read more
Interview: Open Insulin
26 Aug 2016, 9:41 a.m. in #insulin4all USA, Interviews by Elizabeth Pfiester
Currently we’re working on a novel method to produce human insulin, which is not patented, and as far as I know is not patentable. There are variations on normal human insulin to make them longer or shorter acting, which involve very small changes to the sequence that codes for human insulin... Read more
Access to Health Care in the USA
24 Jun 2016, 8:03 p.m. in #insulin4all USA, Global Stories by Zach Toth
In the US we are very lucky to have access to some of the best health care methods and technology in the world. I never have to worry about where my next pen of insulin will come from and I get to try out the latest tech and choose what works best for me, for the most part... Read more
‘‘It would be cheaper for me to die’’
14 Apr 2016, 1:48 p.m. in #insulin4all USA, Global Stories, News & Statements by Elizabeth Pfiester
Since sharing our initial survey data about out-of-pocket costs for insulin and diabetes supplies, we have received even more responses. With an overwhelming number of USA respondents, our survey has collected comment after comment about the outrageous costs faced by Americans who must contend with this financial burden... Read more
My Fight for Information
13 Mar 2016, 2:56 p.m. in #insulin4all USA by Mindy Bartleson
Diabetes has been a big part of my life for a long time, but during my fall semester of my senior year at university in my International Social Work class, I decided to focus on diabetes and access to resources, specifically insulin. Read more
What is Needed to Improve Affordability of Insulin?
16 Dec 2015, 12:12 p.m. in #insulin4all USA by Ryan Knox
We have dozens of insulin products on the market, consisting of human, animal, and analog insulins. Many of the originator products are off patent or soon coming off patent, allowing for generics and biosimilars to enter the market. Yet availability of affordable insulin continues to be a problem... Read more
1922
29 Jul 2015, 6:43 p.m. in #insulin4all USA by Elizabeth Pfiester
“We felt it more humanitarian to prolong the lives of many old and faithful patients rather than attempt to secure marvelous results in a few.” This quote is from Dr. Elliott Joslin regarding his first experiences treating patients with insulin in 1922. Read more